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A STUDY ON PROGNOSTIC SIGNIFICANCE OF NEUTROPHIL 
LYMPHOCYTE RATIO IN PATIENTS WITH STEMI 
 
INTRODUCTION: 
Cardiovascular diseases are responsible for 30% of all deaths worldwide and 
are the number one cause of deaths globally.(1) Cardiovascular diseases caused an 
estimated 17.3 million deaths in a year. Around 40% of these cardiovascular deaths 
are due to coronary heart disease. It is projected that coronary heart diseases will 
remain a leading cause of morbidity and mortality for many years to come. 
Atherosclerosis, the main underlying pathologic process for coronary heart diseases, 
is a chronic disease state of the coronary arteries that slowly develops over decades 
before becoming clinically significant. Its pathophysiology is complex, including 
inflammatory and immunological events which are considered to be of central 
importance in the initiation and progression of atherosclerotic plaques (2). Gradual 
chronic progression of coronary atherosclerosis may result in luminal narrowing 
causing symptoms of angina. However a more acute scenario exists where an abrupt 
change in plaque status causes rapid decrease in luminal patency. ST-elevation 
myocardial infarction (STEMI) is due to red thrombus formation often leads to acute 
vessel occlusion, while for non-ST elevation myocardial infarction (NSTEMI) a non-
occluding (mural) platelet rich thrombus is the cause. 
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The inflammatory markers like neutrophil, lymphocyte and Neutrophil to 
lymphocyte ratio (NLR) have been associated with increased adverse clinical 
outcomes in ST elevation myocardial infarction (STEMI) (3), non-ST elevation 
myocardial infarction (N-STEMI (4).The role of inflammatory markers in the 
development and progress of atherosclerosis has been clarified and several biological 
markers of inflammation predict cardiovascular risk (5). Since it is an inflammatory 
disease, some inflammatory markers have been proposed for the evaluation of the 
cardiovascular risk. Red cell distribution width (RDW) and neutrophil-to-
lymphocyte ratio (NLR) are the two markers of inflammation that are used to 
determine risk of morbidity and adverse cardiovascular outcomes in patients with 
acute myocardial infarction (AMI) (6). 
Inflammatory markers are also known as classic markers of inflammation in 
cardiovascular diseases [7]. NLR was taken to be a potential marker to determine 
inflammation in cardiac and non-cardiac disorders, and to predict long-term 
mortality in patients who underwent percutaneous coronary intervention in patients 
with ST-segment elevation myocardial infarction (STEMI) [8]. As these 
inflammatory marker values are readily available in routine blood count analysis, 
NLR may be used as a cost-effective predictor of inflammation and cardiovascular 
complications [9]. 
The main goal of the treatment of acute myocardial infarction is the early 
restoration of patency of the culprit artery. This could be achieved by either 
fibrinolysis or primary percutaneous coronary intervention (PPCI) [10].No reflow 
can be caused by distal embolization of atherothrombotic debris, thrombus 
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formation, and endothelial dysfunction of the distal arteriolar and capillary bed, 
(including endothelial desquamation and microcirculatory vasospasm, ischemic 
injury, reperfusion injury) and susceptibility of coronary microcirculation to injury. 
Recently, neutrophil/lymphocyte (N/L) ratio was found to be a strong 
predictor of adverse outcomes after PPCI [11].However, its underlying mechanism 
remains unknown. Reason possibly may be due to atherosclerosis, which is an 
inflammatory process, and inflammatory biomarkers have been identified as useful 
predictors of clinical outcomes. 
Neutrophil-to-lymphocyte ratio (NLR) has been advocated recently as a 
prognostic factor even in non-cardiac diseases. This ratio can be accessed easily and 
widely and is inexpensive. There is strong evidence that NLR is associated with 
clinical outcomes. Also, Arbel et al. (2012) with a follow-up of patients for three 
years with cardiovascular diseases reported that NLR is associated with more severe 
CAD (12). 
Previous studies have shown that inflammation acts as a facilitator in the 
induction of supraventricular tachycardia, and that increased inflammatory markers 
have a role in predicting atrial tachycardia.(11). Left ventricular ejection fraction 
(LVEF) is a parameter used for assessment of left ventricular systolic function in 
daily practice and has been shown to be an efficacious predictor of prognosis after 
AMI [13].The relationship between RDW and NLR obtained from complete blood 
count during first admission to hospital and left ventricular systolic functions is 
unknown.  
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Figure 1: Adapted from - Libby P, Ridker PM, Maseri A. Inflammation and 
atherosclerosis. Circulation. 2002 
 “Leukocytes has a major role in initiation and progression of atherosclerosis, 
in acute rupture of atherosclerotic plaques and  superimposed thrombus formation 
[3]. During acute myocardial infarction (AMI), activated-neutrophils breach the 
infarcted zone (14). Contributing to fibrotic scar formation, a cause of rhythm 
disturbance [15]. Furthermore, neutrophils aggregate with platelets to increase 
vascular plugging in the microcirculation [10].and cause a no-reflow phenomenon.  
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Neutrophils prompt the secretion of inflammatory mediators increasing the 
intensity of myocardial ischemia and extending infarct area. Depressed levels of 
circulating lymphocytes are due to elevated cortisol secretion and apoptotic stress 
reactions. Reduced lymphocyte levels were associated with advanced heart failure 
[16] and morbidity in STEMI patients”. 
However, catecholamine release, dehydration or reperfusion treatment may 
artificially elevate the levels of circulating neutrophils and lymphocytes, and reduce 
their truthful prognostic value. Of the haematological indices, the neutrophil/ 
lymphocyte ratio (NLR) has the highest predictive value in predicting MI in high 
risk patients for coronary artery disease [17]. Also, it has been shown that NLR 
predicts the long term mortality in patients hospitalized with ST elevation 
myocardial infarction (STEMI), and in patients undergoing percutaneous coronary 
intervention (PCI). 
 
Complications of Acute Myocardial Infarction 
Complication 
Type Manifestations 
Ischemic Angina, reinfarction, infarct extension 
Mechanical Heart failure, cardiogenic shock, mitral valve dysfunction, 
aneurysms, cardiac rupture 
Arrhythmic Atrial or ventricular arrhythmias, sinus or atrioventricular node 
dysfunction 
Embolic Central nervous system or peripheral embolization 
Inflammatory Pericarditis 
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Ischemic complications 
Ischemic complications can include infarct extension, recurrent infarction, and 
postinfarction  angina.Infarct extension is a progressive increase in the amount of 
myocardial necrosis within the infarct zone of the original MI. This can manifest as 
an infarction that extends and involves the adjacent myocardium, or as a 
subendocardial infarction that becomes transmural.Following fibrinolytic therapy, 
reocclusion of the infarct-related artery (IRA) occurs in approximately 5% to 10% of 
patients by the time of discharge, and in 25% to 30% of patients at 1 year. These 
patients also tend to have a poorer outcome. Reinfarction is more common in 
patients with diabetes mellitus or prior MI. With the advent of primary percutaneous 
coronary intervention (PCI) and stent placement, risk of reinfarction has dropped 
substantially, to approximately 3% during the first 90 days after MI. Recurrent 
infarction in a separate territory may be difficult to diagnose within the first 24 to 48 
hours after the initial event. Multivessel coronary artery disease is common in 
patients with acute MI. In fact, angiographic evidence of complex or ulcerated 
plaques in noninfarct-related arteries is present in up to 40% of patients with acute 
MI.Angina that occurs from a few hours to 30 days after acute MI is defined as 
postinfarction angina. The incidence of postinfarction angina is highest in patients 
with non–ST-elevation MI (approximately 25%), and in those treated with 
fibrinolytics rather than with PCI.The pathophysiologic mechanism of postinfarction 
angina is similar to that of unstable angina—plaque rupture—and should be 
managed in a similar manner. Patients with postinfarction angina have a worse 
prognosis with regard to sudden death, reinfarction, and acute cardiac events, 
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compared with those without such symptoms.Patients with infarct extension or 
postinfarction angina usually have continuous or intermittent chest pain, with 
protracted elevation in the creatine kinase (CK) level and occasionally, new 
electrocardiographic changes.The diagnosis of infarct expansion, reinfarction, or 
postinfarction ischemia can be made with echocardiography or nuclear imaging.  
Mechanical complication 
                     Mechanical complications of acute MI include ventricular septal defect 
(VSD), papillary muscle rupture or dysfunction, cardiac free wall rupture (FWR), 
ventricular aneurysm, LV failure with cardiogenic shock, dynamic LV outflow tract 
(LVOT) obstruction, and right ventricular (RV) failure. 
Ventricular Septal Defect 
VSD formerly occurred in 1% to 2% of patients after acute MI in the 
prethrombolytic era . The incidence has decreased dramatically with reperfusion 
therapy now is generally diagnosed within the first 24 hours after MIThe defect 
usually occurs at the junction of preserved and infarcted myocardium in the apical 
septum with anterior MI, and in the basal posterior septum with inferior MI. VSD 
almost always occurs in the setting of a transmural MI and is more often seen in 
anterolateral MIs. The defect might not always be a single large defect; in 30% to 
40% of patients, a meshwork of serpiginous channels can be identified.Early in the 
disease process, patients with VSD may appear relatively comfortable, with no 
clinically significant cardiopulmonary symptoms. Rapid recurrence of angina, 
together with hypotension, pulmonary edema, and frank cardiogenic shock can 
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develop later in the course.Rupture of the ventricular septum is often accompanied 
by a new harsh holosystolic murmur best heard at the left lower sternal border. The 
murmur is accompanied by a thrill in 50% of cases. This sign is generally 
accompanied by a worsening hemodynamic profile and biventricular failure. 
Therefore, it is important that all patients with MI undergo a careful, well-
documented cardiac examination at presentation and daily thereafter.. 
Echocardiography with color flow Doppler imaging is the best method for 
diagnosing VSD.:Early surgical closure is the treatment of choice, even if the 
patient's condition is stable 
 
Mitral Regurgitation 
MR after acute MI portends a poor prognosis. MR of mild-to-moderate severity is 
found in 13% to 45% of patients following acute MI. Whereas most MR is transient 
in duration and asymptomatic, MR caused by papillary muscle rupture  is a life-
threatening complication of acute MI. Fibrinolytic agents decrease the incidence of 
rupture; however, when present, rupture can occur earlier in the post-MI period than 
in the absence of reperfusion. Although papillary muscle rupture was reported to 
occur between days 2 and 7 in the prefibrinolytic era, the SHOCK (SHould we 
emergently revascularize Occluded Coronaries in cardiogenic shocK?) Trial Registry 
demonstrated a median time to papillary muscle rupture of 13 hours.Papillary muscle 
rupture is found in 7% of patients in cardiogenic shock and contributes 5% of the 
mortality after acute MI 
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.Left Ventricular Free Wall Rupture 
While LV Free wall rupture was more common before the era of reperfusion, it now 
affects only 0.5% of MI patients. However, FWR carries with it a substantial 
mortality rate of 20%.the timing of cardiac rupture is within 5 days of infarction in 
50% of patients and within 2 weeks in 90% of patients. Free wall rupture occurs only 
among patients with transmural MI . Risk factors include advanced age, female 
gender, hypertension, first MI, and poor coronary collateralization.Compared with 
individuals who did not receive fibrinolytic agents, MI patients administered such 
drugs were found to experience Free wall rupture earlier in their clinical course. 
However, their overall risk of Free wall rupture was not increased  Although any 
wall can be involved, cardiac rupture most commonly occurs at the lateral wall.FWR 
occurs at three distinct intervals, with three distinct pathologic subsets. Type I 
increases with the use of fibrinolytics, occurs early (within the first 24 hours) and is 
a full-thickness rupture. Type II rupture occurs 1 to 3 days after MI and is a result of 
erosion of the myocardium at the site of infarction. Type III rupture occurs late and 
is located at the border zone between infarcted and normal myocardium 
Pseudoaneurysm 
                Pseudoaneurysm is caused by contained rupture of the LV free wall. The 
aneurysm may remain small or undergo progressive enlargement. The outer wall is 
formed by the pericardium and mural thrombus. The pseudoaneurysm communicates 
with the body of the left ventricle through a narrow neck whose diameter is by 
definition less than 50% of the diameter of the fundus.Some pseudoaneurysms 
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remain clinically silent and are discovered during routine investigations. However, 
some patients have recurrent tachyarrhythmia, systemic embolization, and heart 
failure.surgical intervention is recommended for all patients, regardless of symptoms 
or the size of the aneurysm, to prevent sudden death. 
 
Left Ventricular Failure and Cardiogenic Shock 
LV dysfunction is to be expected after an acute MI. The degree of dysfunction 
correlates with the extent and location of myocardial injury. Non-infarcted 
myocardium can also become temporarily hypokinetic or akinetic due to ischemic 
"stunning." Patients with small, more distal infarctions may have discrete regional 
wall motion abnormalities with preserved overall LV function because of 
compensatory hyperkinesis of the unaffected segments. Prior MI, older age, female 
gender, diabetes, and anterior infarction are risk factors for development of 
cardiogenic shock 
In the late 1960's, Killip and Kimbal developed a classification scheme to categorize 
patients' prognosis based on their physical exam findings  Individuals were classified 
into four subsets, from "no evidence of congestive heart failure" (Class I) to 
"cardiogenic shock" (Class IV). The authors reported a 67% mortality rate for Class 
IV patients. 
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Incidence of Heart Failure in Acute Myocardial Infarction 
Killip 
Class 
Characteristics 
Patients 
(%) 
30-Day Mortality 
(%) 
I No evidence of congestive heart 
failure 
32 6 
II Rales, ↑ jugular venous distention, 
or S3 
38 17 
III Pulmonary edema 10 38 
IV Cardiogenic shock 19 67 
 
Right Ventricular Failure  
 Mild RV dysfunction is common after MI of the inferior or inferoposterior 
wall, with an incidence of approximately 40%. Hemodynamically significant RV 
impairment occurs in only 10% of patients with these types of MI, The degree of RV 
dysfunction depends on the location of the right coronary artery occlusion. Only 
proximal occlusions of the right coronary artery (proximal to the acute marginal 
branch) result in marked dysfunction. 
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Ventricular Aneurysm 
Patients who do not receive reperfusion therapy are at greatest risk for developing 
this complication (in 10%-30%). Among the various infarct locations, patients with 
apical transmural MIs are at the highest risk for aneurysm formation, followed by 
those with posterior-basal infarcts. Acute decompensated heart failure and even 
cardiogenic shock can develop as a result of a large LV Revascularization is 
beneficial for patients with a large amount of viable myocardium around the 
aneurysmal segment. 
  
Dynamic Left Ventricular Outflow Tract Obstruction 
  Dynamic LVOT obstruction is an uncommon complication of acute anterior 
MI .This event is dependent on compensatory hyperkinesis of the basal and 
midsegments of the left ventricle in patients with distal LAD infarcts. Predictors of 
enhanced regional wall motion in noninfarct zones are the absence of multivessel 
disease, female gender, and higher flow in the infarct-related vessel.. 
Arrhythmic Complications 
Ventricular arrhythmia is a common complication of acute MI, occurring in 
almost all patients, even before monitoring is possible. It is related to the formation 
of re-entry circuits at the confluence of the necrotic and viable myocardium, as well 
as to irritable ischemic myocardium.Premature ventricular contractions occur in 
approximately 90% of patients with acute MI.  
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At the other end of the spectrum, the incidence of ventricular fibrillation (VF) 
is approximately 2% to 4%. Although lidocaine has been demonstrated to reduce 
somewhat the rate of primary VF in patients with MI, there is no survival benefit and 
there may be excess mortality. Therefore, it is not recommended that patients receive 
prophylactic lidocaine therapy.Amiodarone may be used in patients with MI with 
nonsustained ventricular tachycardia (VT), or after defibrillation for VF. 
Polymorphic VT is a rare complication of acute MI, usually associated with 
recurrent ischemia.  
 
Embolic Complications 
The incidence of clinically evident systemic embolism after MI is less than 
2%. The incidence increases in patients with anterior wall MI. The overall incidence 
of mural thrombus after MI is approximately 20%. Large anterior MI may be 
associated with mural thrombus in as many as 60% of patientMost emboli arise from 
the left ventricle as a result of wall motion abnormalities or aneurysms. Atrial 
fibrillation in the setting of ischemia can also contribute to systemic 
embolization.The most common clinical manifestation of embolic complications is 
stroke, although patients may have limb ischemia, renal infarction, or mesenteric 
ischemia. Most episodes of systemic emboli occur within the first 10 days after acute 
MI.  
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Pericarditis 
The incidence of early pericarditis after acute MI is approximately 10%. This 
inflammatory condition usually develops between 24 and 96 hours after 
MI.Dressler's syndrome, or late pericarditis, occurs with an incidence between 1% 
and 3%, typically 2 to 8 weeks after MI.he pathogenesis of acute post-MI pericarditis 
is an inflammatory reaction in response to necrotic tissue. Acute pericarditis thus 
develops more often in patients with transmural MI. The pathogenesis of Dressler's 
syndrome is unknown, but an autoimmune mechanism involving circulating 
myocardial antigens has been suggested 
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AIM 
 To   evaluate  the role of neutrophil/ lymphocyte ratio (NLR ) in determining the 
prognosis of and risk of major post-STEMI adverse events. 
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REVIEW OF LITERATURE 
The link between inflammation and myocardial infarction (MI) has been 
suggested more than 50   years ago. Since then, evidences supporting their 
relationship have been studied in various basic sciences, epidemiological and clinical 
studies. 
Obtaining peripheral leukocyte count is a cheap and widely available mode to 
assess the presence of any inflammation. According to the literature, MI is 
accompanied with peripheral leucocytosis [18] and leucocytosis is associated with 
higher rates of short-term mortality and heart failure after myocardial infarction. 
For the past two decade various inflammatory markers were evaluated in the 
atherosclerosis cascade beginning from stage of inflammation in vascular bed to 
vulnerable plaque like plaque rupture and erosion, which ultimately leads to clinical 
events as acute coronary syndrome. At the stage of acute coronary syndrome various 
markers were evaluated to identify and quantify myocardial necrosis and myocardial 
dysfunction. These markers were used for risk stratification and to assess clinical 
outcome after AMI.  
 Atherosclerosis begins well from the fetal life. Normally the circulating lipids 
will not enter into the intact endothelium. When the individual consumes lipid (fat) 
rich diet endothelial adhesion molecules like ICAM-1 and VCAM-1 and E-Selectin 
were expressed in the endothelium which stimulates Monocyte chemo attractant 
protein (MCP-1).This MCP-1 stimulates leukocyte to invade intima and initiates the  
inflammatory process with in the vessel wall. This ICAM-1, VCAM-1, were 
elevated in acute coronary syndrome. 
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Factors like thrombomodulin which indicates endothelial integrity are also 
increased in ACS. Since the monocytes were actively participating in inflammation 
monocytes were elevated in acute coronary syndromes. Recently studies are 
published which evaluated neutrophil to lymphocyte ratio in stable angina pectoris, 
unstable angina, Non-ST Elevation Myocardial infarction and ST Elevation 
Myocardial infarctions. 
Platelets were also elevated in acute coronary syndromes which are 
determined by mean platelet volume. The increased platelet volume in acute 
coronary events strongly correlates with thrombus burden.The platelets to 
lymphocyte ratio are also elevated in acute coronary events which strongly correlate 
with severity of coronary artery disease.   
Natural History of Atherosclerotic Plaques 
  Early atherosclerotic lesions consist of two distinct non atherosclerotic 
intimal lesions referred to as adaptive intimal thickening and intimal xanthoma 
(“fatty streak”). There is substantial evidence that while some human lesions may 
begin as intimal xanthomas, the most likely precursor lesion leading to the majority 
of obstructive lesions is likely the adaptive intimal thickening. As shown by the 
Pathobiologic Determinants of Atherosclerosis in Youth (PDAY) studies, sites 
where fatty streaks in young individuals are commonly seen, such as thoracic aorta 
and mid – right coronary arteries, are not associated with progression in older 
individuals. Also, intimal thickening in children occurs in adults and is thought to be 
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a precursor the coronary obstructive lesions. These intimal masses consist mainly of 
smooth muscle cells (SMCs) in a proteoglycan rich matrix  
  The transition between early lesions of atherosclerosis and the more 
advanced fibro atheroma is characterized by the invasion of extracellular lipid pools 
by macrophages. As a result, lipid pools form in regions of the proteoglycan – rich 
matrix devoid of smooth muscle cells. A variable number of T lymphocytes are also 
observed at this stage, but a true necrotic core is absent. Areas of lipid polls may also 
contain free cholesterol appearing as cholesterol clefts on paraffin – stained sections.  
Accumulated free cholesterol may be observed to varying degrees in early 
fibro atheroma, but is more prominent in late fibro atheroma with a well – defined 
necrotic core. By contrast, very few B lymphocytes are found within the developing 
plaque and are restricted mostly to the adventitia. It has been proposed that the 
presence of macrophages in lesions of PIT are at a more advanced stage of 
atherosclerotic development. (Figure 2) 
Accumulated apoptotic material was associated with a marked acceleration of 
atherosclerosis accompanied by decreased anti-inflammatory (IL-10) production by 
protective T-cells.  
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Figure 2 Mechanism of inflammatory mechanism in atherogenesis (adapted from 
Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-126. 
 
 In addition to lactadherin, other putative molecules in plaques potentially 
linked to efferocytosis and defective clearance of apoptotic debris include Fas ligand 
and transglutaminase -2 (TG2). These correlative studies provide potential 
explanations for necrotic core expansion and lesion progression.  
For successful addition of  novel therapeutics, we need to focus our insights into 
the complex pathogenesis of atherogenesis, find safe and effective compounds 
capable for directly suppressing plaque inflammation and lipoapoptosis, and to 
identify high-risk patients who are expected to benefit from distinct pharmacological 
interventions.  
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Around 100 years age, in the early 20th century, an officer at the Military Medical 
Academy in St Petersburg (Russia) named Anitschkov found the atherosclerosis 
development in rabbits by feeding them a high-fat diet consisting of  meat, eggs and 
milk. Consequently, pathogenesis of atherosclerosis was found to be straight-forward 
and unpretentious, when consuming a fat-rich diet, lipid levels increased in the 
plasma which resulted in cholesterol deposition in the arterial wall- first stage of 
atherosclerosis. This was a dominant model in the 20th century, based on the fact that 
atherosclerosis reflected a passive accumulation of cholesterol in the sub endothelial 
compartment. However, this simple concept was refuted. With the birth of the 
millennium, a shift in our understanding of the pathogenesis occurred, which 
considered atherosclerosis a complex and dynamic process, specifically a chronic, 
smouldering, inflammatory disease of the arterial wall. With progress in science , 
parts and pieces of this thrilling disease are falling into place. 
ATHEROGENESIS 
 Atherogenesis refers to the formation of atherosclerotic plaques in the arterial 
wall. Dysfunction of the arterial luminal wall endothelium, with irritative stimuli like 
smoking, hypertension, dyslipidaemia and systemic inflammation, is considered to 
be one of the initiators of atherogenesis. Lipid carrying cholesterol leak into the sub 
endothelial space and are modified by oxidation within the arterial wall, wherein 
they produce an inflammation to restore local homeostasis.  
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Local inflammatory reactions cause upregulation of endothelial adhesion 
molecules producing adherence of immune cells, including monocytes. In the sub 
endothelium, the monocytes differentiate into macrophages. Within a lipid rich and 
toxic microenvironment, the functions of macrophages are divided into two distinct 
properties. Modified Leaked lipid particles can induce a sterile cold inflammatory 
reaction – similarly to the classical hot inflammation, but with a less energy 
expenditure – through Toll-like receptors they get engulfed via the scavenger 
receptors. Accumulation of intracellular cholesterol ,which is the first macroscopical 
stage of atherogenesis - foam-cell formation and fatty streaks. At a later stage, 
macrophage-derived foam cells lead to the formation of an advanced plaque creating 
a lipid-rich necrotic core consisting of  extracellular lipids with cellular debris. 
Ultimately , atherosclerosis becomes manifests clinically as plaque rupture and intra 
luminal thrombosis which leads to ‘acute’ distal ischemia. In a minority of cases, 
luminal obstruction due to slowly, progressive, flow-limiting stenosis, no longer be 
compensated by outward remodelling  of the vessel, and may give rise to ‘chronic’ 
distal ischemia. 
LIPID ACCUMULATION 
 Lipids have a key role in atherogenesis; low-density lipoprotein (LDL) 
cholesterol (LDL-C) levels correlate strongly with CV risk. Observation in rural 
China even traditional risk factors, such as hypertension, were not associated with 
atherosclerosis due to  very low LDL-C levels, led to the concept that LDL-C had an 
important  role throughout the course of atherogenesis. However, the LDLs success 
story has an other side of the coin. Despite optimal statin treatment, a substantial 
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residual CV risk remains. Even statin combinations with other lipid-modulating drug 
have failed to further decrease this residual risk, including the cholesterylester-
tranfer protein inhibitors, nicotinic acid derivatives and ezetimibe. With the 
identification of the causal role of inflammation in atherogenesis, anti-inflammatory 
agents are being considered as the therapeutic agents to further decrease the residual 
CV risk in addition to statins. 
NONRESOLVING INFLAMMATION IN ATHEROSCLEROSIS 
Till date, the inflammatory response has been widely accepted to unify 
atherogenesis from initiation to progression, despite our understanding of the exact 
primary pathogenic trigger and regulation of inflammation within the arterial wall is 
still unidentifiable. In early atherosclerotic lesions, endothelial dysfunction and 
inflammatory signaling induce an adaptive response, making an effort to adapt to the 
noxious, lipid-rich conditions and restore tissue functionality. However human 
nature miserably fails and the majority of atherosclerotic plaques succumb to chronic 
non resolving inflammation leading to a vicious circle. 
In comparison with the classical hot inflammatory responses being triggered 
by bacterial pathogens or tissue injury, the underlying mechanism in the atherogenic 
inflammation is LDL-C. Following subendothelial modification LDL a metabolical 
induced inflammation is triggered, known as metaflammation. Metaflammation 
includes not only the sterile cold immune response, but also the intracellular 
metabolic changes due to the noxial uptake.  
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Native LDL mainly found in the blood stream, is relatively inert to immune 
responses. However, slightly modified LDL products cause inflammatory responses 
through communication with residential tissue macrophages by activation of various 
receptors, like the Toll-like receptors. This sterile and cold inflammatory phase is 
looked after by the well-established M0, M1 and M2 macrophages [39].  
Highly oxidized LDL (oxLDL) particles, modified at both the lipid and the 
protein parts, have different properties compared with their less-modified precursors. 
oxLDL are recognized by macrophages via scavenger receptors (i.e.,CD36) which 
results in the infinite uptake of oxLDL in the macrophage. Excess intracellular 
cholesterol accumulation in the macrophage must be exported, through cholesterol 
efflux, or esterified for storage in cytoplasmic lipid droplets to prevent the lipo toxic 
effects associated with elevated free cholesterol within the endoplasmic reticulum. 
Paradoxically, extra oxLDL loading of the macrophage rather than activation results 
in the suppression of the inflammatory machinery of the cell and finally drives the 
lipid laden macrophages into apoptosis[40]. 
Apart from metaflammation, parainflammatory processes are present to 
restore local haemostasis in the arterial wall. In general a controlled inflammatory 
response aimed at restoration is beneficial. If regulation is lost it may become 
detrimental. In atherosclerosis, parainflammatory processes leads to endothelial 
dysfunction, thickening of intima, calcification, smooth muscle cell proliferation and 
neoangiogenesis, which are  hallmarks of advanced atheroma in CV disease. These 
can be caused by a signalling pathway-wnt signalling. Wnt is secreted by 
macrophages in a lipid-rich microenvironment, and also in the plaque.  
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Ultimately, continuous oxidation of LDL aggravates metaflammation with 
parainflammatory processes not able to clear oxidized LDL products and in 
resolving a chronic inflammation inside the atherosclerotic plaque.  
APOPTOSIS IN A LIPID-RICH ENVIRONMENT 
 Latest research found that atherosclerosis not only involves systemic 
dyslipidaemia and arterial inflammation, and also a third component; intra plaque 
lipoapoptosis. Lipoapoptosis is a process of programmed cell death due to high 
concentrations of intracellular oxLDL, leading to the nonresolving metaflammation 
in the central necrotic core of an atheroma. For understanding lipoapoptosis, the 
current authors, and others, suggested a new type of macrophage called Mox, which 
also takes the lipid metabolism and homeostasis inside the plaque macrophages, 
foam cells Lipid metabolism intracellularly in macrophages is delicately regulated. 
Cytosolic lipid balance is done by regulating the influx like the CD36 receptor, 
distribution like FABP chaperone and efflux extracellular acceptors like apoA1 via 
cholesterol efflux transporters (i.e., ABCA1/G1).These systems fail in the presence 
of severe metabolic ( oxLDL loading) or inflammatory stresses, which turn the 
cytosol into an unfriendly environment with less than good outcomes (i.e., 
lipoapoptosis) and driving atherogenesis independent of cold inflammatory 
processes. 
 In humans the immune system is not capable of handling highly oxidized 
lipids since M0 and M2 macrophages show higher sensitivity to oxLDL loading. So  
macrophages in a lipid-rich-to-toxic microenvironment are metabolically trapped in 
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the atheromatous plaque, because of increased expression of netrin-1. They are 
found to become oxLDL loaded and apoptotic, in spite of  their constancy and 
perseverance to clean LDL-C generics. Apoptosis induced by lipids is known as 
lipoapoptosis.  
Apoptosis of oxLDL-loaded macrophages ultimately leads to a release of 
further oxLDL precursors and necrotic material leading to a vicious circle of 
lipoapoptosis and progression of plaque[19]. These occur in the central core of a 
late-stage atheroma finally leading to plaque rupture. Cold inflammation is seen in 
the shoulder region of the core, or in the smooth muscle or endothelial cells near the 
core. Lipoapoptosis predominantly occurs in the vicinity of the central core of an 
advanced atheroma, leading to unresolving  inflammation in atherosclerosis. 
Biomarkers and Coronary Syndromes 
 A biomarker for cardiovascular disease should reflect important 
pathophysiological processes in atherogenesis and plaque destabilization with the 
goal of enhancing stratification of at-risk patients where various treatment strategies 
can be matched to the appropriate level of risk. Conceptually, the failure of candidate 
biomarkers to predict cardiovascular events has been attributed to their inability to 
represent a multi complex disease or they were proven indicators of epiphenomena 
independent of the disease itself. Consistent with these observations, the prototypical 
marker CRP does not play a direct pathogenic role, but represents a potential 
downstream inflammatory activity. Regardless, potential biomarkers that are more 
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reflective of systemic inflammation and not necessarily vascular inflammation may 
fail because they will incur a high rate of false-positives. 
 Lipid-related biomarkers, specifically LDL-C, represent the prototypical 
biomarkers of coronary artery disease. Despite the significance of cholesterol in 
acute coronary syndromes, however, many individuals who experience MI have 
cholesterol concentrations at or below recommended levels. notwithstanding, 
patients receiving pharmacotherapy for dyslipidaemia, who have LDL levels at 
currently mandated targets or below, still remain at risk for MI. Indeed, having a 
marker that may identify plaques that rupture potentially meets an important unmet 
clinical need because greater than 66% of all MIs occur in coronary arteries with 
greater than 50% stenosis on coronary angiography. Thus, the apparent divergence 
of clinical risk associated with traditional lipid biomarkers and adverse outcome 
highlights the necessity for improving the ability to predict cardiovascular events. 
Recent work has focused on whether plasma markers of inflammation can 
noninvasively diagnose and prognosticate coronary artery disease (CAD) and other 
forms of atherosclerosis. Inflammatory biomarkers, or “acute-phase reactant 
proteins,” namely CRP, fibrinogen, serum amyloid (SAA) and other less notable 
proteins, such as type II secretory phospholipase A2 (sPLA2-II), have been recently 
studied. Indeed, acute phase reactants increase greatly during systemic inflammatory 
conditions, such as sepsis, rheumatoid arthritis, or inflammatory bowel disease. In 
addition to CRP, other inflammatory biomarkers of recent clinical interest include: 
IL-6, IL-3, IL-8, M-CSF, and soluble CD40 ligand. 
  
27 
 
 Recent autopsy study from our laboratory, serum levels of hs-CRP were 
significantly elevated in patients dying suddenly of plaque rupture, erosion, or stable 
plaque relative to control patients where death was attributed to non-coronary causes 
independent of age, body mass index, and smoking (control hs-CRP 1.4 
micrograms/dl versus sudden death 2.7 micrograms/dl, P < 0.0001). 
Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) and Cardiovascular 
Disease Risk 
 Another potentially important biomarker of inflammation receiving clinical 
attention of late in relation to atherosclerosis and its adverse outcomes is lipoprotein- 
associated phospholipase A2 (Lp-PLA2), a unique phospholipase that circulates 
primarily bound to low –density lipoprotein. A number of recent publications 
support the role of Lp-PLA2 as a cardiovascular risk marker independent of and in 
addition to traditional risk factors. Functionally, Lp-PLA2 is an enzyme capable of 
specifically hydrolyzing oxidized phospholipids with breakdown products of 
oxidized free fatty acids and lysophosphatidylcholine.  
Evidence of Lp-PLA2 as a Clinical Biomarker of Cardiovascular Risk 
 That Lp-PLA2 is an independent cardiovascular risk marker and an additive 
risk factor for cardiovascular mortality. Currently, although the clinical value of Lp-
PLA2 as an inflammatory biomarker capable of predicting future coronary events is 
becoming increasingly apparent, less is known of whether specific targeting of Lp-
PLA2 can actually modify the plaque. 
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Serum Ischemia Markers 
Cardiac troponins (cTn) play a pivotal role in modern diagnosis, risk 
assessment, and selection of therapy for patients with suspected acute coronary 
syndromes. Troponins alone fail to completely characterize risk among patients with 
ACS, likely because they do not account for pathophysiological process beyond 
myocardial injury. Fourth, cTn release is often not detectable until 6-9 hours 
following injury, leading to delays in diagnosis and appropriate management. The 
marker remains elevated for 7-14 days, rendering it inadequate to detect recurrent. 
Best studied biomarkers under consideration to complement troponins include the B-
type natriuretic peptides and C-reactive protein (CRP). Clinicians should demand a 
very high level of evidence before considering any of these markers for 
incorporation into clinical practice (Table 10-1) 
Inflammation in Cardiovascular Disease 
 Deciphering the process by which stable atherosclerotic plaques become 
vulnerable, rupture, and subsequently lead to acute vascular ischemia is a major 
issue in cardiovascular research. At the core of our understanding of how this 
process occurs is a change in our appreciation of atherosclerosis as not merely a 
progressive lipid storage disease, but also as a complex process characterized by 
endothelial dysfunction and inflammation. From the initial recruitment of 
inflammatory cells to the diseased endothelium to eventual rupture of a vulnerable 
plaque, inflammation and hyperlipidaemia work in tandem to promote 
atherosclerosis. Stable plaques are characterized by a predominance of smooth 
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muscle cells and few inflammatory cells, whereas unstable plaques are characterized 
by accumulations of inflammatory cells. As atherosclerotic disease progresses, the 
inflammatory environment eventually overwhelms the plaque’s capacity for repair, 
resulting in fissure and erosion of the fibrous cap, and subsequent plaque rupture. 
Inflammatory signals promote thrombogenicity of the atheroma via effects on tissue 
factor and various other mediators of coagulation. This results in thrombus 
formation, tissue ischemia, and eventual infarction. As ischemic heart disease 
progresses to heart failure, the chronic activation of inflammatory mediators 
continues to exert deleterious effects on the heart and the circulation, contributing to 
further progression of myocardial dysfunction. Thus, from plaque inception to 
rupture and subsequently to progressive deterioration of cardiac function, 
inflammation plays a central role in atherosclerotic cardiovascular disease. 
 Patients presenting with a suspected ACS may appear in the acute care 
environment anywhere along a continuum of absolutely no cardiac disease 
mimicking a cardiovascular event, extending to acute myocardial ischemia 
manifested as unstable angina (UA). Indeed, our current diagnostics are 
predominantly oriented toward the terminal events in the ACS cascade, after 
necrosis has already occurred. Newer diagnostic approaches focus on events that 
potentially precede the occurrence of myocellular necrosis – during the period before 
cellular injury is irreversible – and offer the hope of improved diagnostic and 
prognostic accuracy. 
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Inflammatory Markers 
 Inflammation plays a central role in ACS from atherogenesis to plaque 
progression, plaque rupture, thrombosis, and the immune response to ischemic 
cardiac injury. A number of protein and nucleotide products implicated in the 
inflammatory processes surrounding ACS have been investigated as potential 
biomarkers (18,19)    . 
 
C-REACTIVE PROTEIN 
 It is an acute phase reactant and a marker of non specific inflammation anywhere 
in the body. Conventional CRP kits will not detect mild elevation less than 6mg/dl. 
Hence the newer parameter in the last decade hs-CRP which detects the subtle elevation 
strongly correlates with cardio vascular events. The patho physiological role is still not 
understood whether it plays significant role in plaque destabilization. In JUPITER trial 
treatment with rosuvastatin clearly reduces LDL and hs-CRP and reduction in hs-CRP 
has independent advantage over LDL reduction on CV events (18,19) .    
Myeloperoxidase (MPO): 
 Myeloperoxidase (MPO) is a heme containing peroxidase that is secreted 
upon leukocyte activation and degranulation and is the predominant component of 
neutrophil granules; it is also found in monocyte and macrophage granules.(23). In 
addition to its role in innate immunity, MPO is also involved in multiple stages of 
atherosclerosis. It contributes to foam cell production by stimulating low density 
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lipoprotein oxidation and uptake by macrophages, and it promotes endothelial 
dysfunction by consuming nitric oxide. Additionally, in post – mortem studies, 
ruptured, culprit plaques contain a higher concentration of MPO may promote 
disruption of atherosclerotic plaques by activating matrix metalloproteinases 
(MMPs), which leads to the destruction of the fibrous cap that protects the 
procoagulant core from the bloodstream. Specifically, the MMP isoform located in 
macrophages closest to the fibrous cap is uniquely activated by MPO oxidation. 
Finally, individuals with total or subtotal MPO deficiencies appear to be protected 
from cardiovascular disease, and those with promoter region polymorphisms 
associated with decreased MPO expression have less angiographic evidence of 
coronary artery disease, fewer MIs, and a reduced incidence of cardiac death (18,19) 
. MPO’s possible role in plaque destabilization makes it a candidate marker for 
evaluation of patients with suspected ACS. Elevation of MPO may signify plaque 
rupture in advance of evidence of cardiac necrosis, allowing for earlier diagnosis of 
ACS and better targeting of therapy. 
 In a recent case control study, MPO levels were significantly higher among 
individuals with ACS than those with normal coronary angiograms or stable 
coronary artery disease (CAD). Several larger, prospective observational studies 
have reported associations between MPO and various clinical outcomes. Brennan et 
al. evaluated the diagnostic and prognostic value of MPO in 604 patients who 
presented to the emergency department with chest pain. MPO levels measured upon 
presentation were associated with a significantly increased risk of death, MI, and 
revascularization at 30 days and six months. .(23) 
  
32 
 
 In a sub study from the c7E3 Fab Antiplatelet Therapy in Unstable Angina 
(CAPTURE) trial of patients with ACS randomized to abciximab or placebo, Baldus 
et al. demonstrated that MPO levels greater than 350 ug/L were associated with an 
HR of 2.25 [95% CI 1, 32-3.82] for death or MI at six months.MPO, like other 
inflammatory markers, is elevated in a variety of inflammatory conditions and 
infections, which may confound its use both in research and in practice.  
MCP-1 
 Monocyte chemoattractant protein -1 (MCP -1) is a CC family chemokine 
produced by monocytes, vascular smooth muscle cells, and endothelial cells. It 
mediates pro inflammatory effects by binding to the CCR2 receptor in monocytes, T 
lymphocytes, natural killer cells, and basophils. MCP-1 is involved in the initiation, 
progression, and destabilization of atherosclerotic disease, as well as in a harmful 
post infarction inflammatory response. Oxidized LDL up- regulates endothelial cell 
synthesis of MCP – 1. This contributes to atherogenesis by causing sub endothelial 
recruitment and activation of monocytes, as well as initiation of foam cell formation. 
Progression of atherosclerotic disease is also promoted by MCP -1, which stimulates 
smooth muscle cell proliferation and plaque neo vascularization. Additionally, MCP 
– 1 may which leads to fibrous cap degradation, and by up – regulating tissue factor 
expression which has pro coagulant effects. Finally, MCP – 1 is involved in post 
infarct inflammation. However, the continued activity of MCP – 1 results in adverse 
ventricular remodelling. Therefore, in ACS, MCP – 1 may be a marker of increased 
atherosclerotic burden and possibly adverse cardiac remodelling.(18,19) 
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Neopterin 
 Neopterin is small pteridine derivative produced by monocytes and 
macrophages as a by – product of guanosine triphosphate (GTP) degradation. 
Neopterin has been implicated both in atherogenesis, by recruiting inflammatory 
cells into the vascular wall via induction of cellular adhesion molecules on the 
surface of endothelial cells, and in thrombosis, by increasing tissue factor 
production. Circulating levels of neopterin appear to reflect macrophage activity, and 
have been used as a marker of cellular immunity in various inflammatory, infectious, 
and malignant diseases, as well as following organ transplantation. Levels also have 
been shown to be elevated in patients with CAD (18,19) .     
Osteoprotogerin 
 Osteoprotogerin (OPG) is a glycoprotein belonging to the tumour necrosis 
factor (TNF) receptor family that is produced by a variety of cells types, including 
osteoblasts, vascular smooth muscle cells, and endothelial cells. Its functions as a 
decoy receptor for receptor activator of nuclear factor kappa – B ligand (RANKL) 
and TNF-related apoptosis – inducing ligand (TRAIL), and has been linked to the 
calcification and inflammatory processes involved in atherosclerosis. It is unclear 
whether OPG promotes atherosclerosis or is released as a compensatory defence 
mechanism in the setting of vascular disease (22). Observational data suggest that 
serum OPG is a marker of atherosclerotic burden. OPG is elevated in patients with 
CAD, and its levels correlate with the extent of disease, as determined by 
angiography or calcium scanning, Ischemia – Modified Albumin. 
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 Oxidative stress and other poorly described physiological processes occurring 
in the setting of myocardial ischemia cause modifications to circulating albumin. 
The resulting changes, termed “ischemia modified albumin” (IMA), result in a 
diminished capacity for binding transition metals – specifically cobalt. This has 
resulted in the development of the albumin cobalt binding (ACB) test for 
measurement of IMA as reflective of the presence or absence of myocardial 
ischemia. Studies have demonstrated a very rapid rise IMA following induced 
myocardial ischemia, which resolves over the next 6-12 hours, suggesting that within 
the appropriate time periods this marker may correlate with the presence of ischemia. 
Confounders to IMA that have been described include: stroke, end- stage renal 
disease, severe cirrhosis and end- stage cancers. While these predominantly 
represent other expected causes of ischemia, it is unlikely that the use of IMA will 
generate specific testing results. Its greatest use may be in the exclusion of potential 
ischemic syndromes. As such, the ACB test for IMA was FDA- cleared as a serum 
biomarker of cardiac ischemia and risk stratification tool in suspected ACS in the 
following manner: discharge of patients may be considered if the ECG is non 
diagnostic for ischemia, the cardiac troponin is negative, and the IMA test is also 
negative. (18,19). 
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Emerging Markers: 
Choline and Unesterified Fatty Acids 
 Although not yet clinically available, both whole blood choline and 
unesterified free fatty acids have promise for the diagnostic evaluation of patients 
with coronary ischemia, but without myocardial necrosis. The origin of both markers 
remains unclear, but a metabolic alteration within myocytes (from aerobic to 
anaerobic metabolism) is suspected. Both markers have been shown to be elevated 
among patients with coronary ischemia, but negative necrosis markers, and may 
provide prognostic information. Larger studies of choline and unesterified free fatty 
acids as markers of coronary ischemia are awaited. (26). 
Evidence that inflammation contributes to the natural history of atherosclerosis from 
earliest fatty streaks to plaque rupture is well established. The cellular components of 
atherosclerosis, in particular inflammatory cells and their mediators, are now 
identified as biological determinants responsible for local complications and acute 
clinical events. The Framingham Heart Study first established the concept of risk 
factor analysis for coronary heart disease in 1961 where hyperlipidaemia, smoking, 
diabetes, hypertension, family history, age, and sex were identified. This scheme was 
further modified in 1998 as risk categories (age, cholesterol, etc.) were assigned a 
point scale of very low, low, moderate, high, and very high risk with estimated risks 
for coronary heart disease over a ten-year period based on the Framingham 
experience in men and women 30 to 74 years old at baseline. Despite its utility, this 
modified scheme falls short of predictive values for patients identified with 
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intermediate risk scores requiring screening based on visualization of the actual 
plaque. 
 Consistent with this notion, atherosclerosis is a focal disease where lesions 
are more common at branch points at sites of low shear in contrast to high shear 
areas, the latter being resistant to plaque formation. Early lesion development is 
marked by lipid retention within a proteoglycan-rich neo intima with activation of 
endothelial adhesion molecules allowing the attachment and diapedesis of 
monocytes. The initial step of monocyte invasion of the neo intima cannot be 
overemphasized because inflammatory macrophages play a significant role 
throughout all phases of atherosclerosis progression. Given that further 
improvements in risk prediction have occurred by the assessment of inflammatory 
biomarkers such as C- reactive protein (CRP), homocysteine, and lipoprotein 
associated phospholipase A2 (LpPLA2), assessment of systemic inflammatory status 
has become important in overall risk stratification. 
GDF-15 
Growth differentiation factor – 15 (GDF-15) is a member of the transforming 
growth factor- β (TGF – β) family, and was first described as macrophage inhibitory 
cytokine 1 (MIC – 1) because it is expressed by activated macrophages in response 
to various pro inflammatory mediators (IL -1, macrophage colony stimulating factor, 
TNF – alpha). Since then it has also been described as placental bone morphogenetic 
protein (PLAB), placental transforming growth factor B (PTGF – B), and prostate – 
derived factor (PDF). Only recently was an in vivo function assigned to GDF-15, 
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when Kempf et al. showed that GDF – 15 expression and secretion is massively up – 
regulated by cardiomyocytes directly exposed to both transient and sustained 
ischemia. The protein appears to protect the myocardium from ischemia/ reperfusion 
injury by promoting cellular survival and limiting the extent of infarction.(29) 
Initial clinical evaluation of GDF – 15 focused on atherosclerosis. In a small 
nested case – control analysis from the Women’s Health Study, baseline GDF – 15 
levels were significantly higher among women who subsequently experienced 
myocardial infarction (MI), stroke, or cardiac death than among those free of such 
events through four years of follow-up. 
ST2. ST2 is an interleukin (IL)-1 receptor family protein synthesized as both 
a membrane bound receptor (ST2L) and a soluble receptor (sST2). In response to 
biomechanical stress, cardiac fibroblasts upregulate expression of both sST2 and its 
ligand (IL – 33). Binding of IL – 33 to ST2L initiates anti hypertrophic signalling 
pathways in cardiomyocytes that appear to be cardio protective, as targeted deletion 
of the ST2 gene in mice enhances cardiac hypertrophy and fibrosis, leading to left 
ventricular dysfunction and reduced survival.(30) 
 Subsequently, Shimpo et al. performed a larger evaluation of ST2 levels in 
810 STEMI patients enrolled in the Thrombolysis in Myocardial Infarction (TIMI) 
14 and 23 trials. sST2 levels began to rise approximately three hours after 
presentation and peaked at 12-24 hours, with higher values observed among 
individuals with larger infarcts. 
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H-FABP 
 Heart – type fatty acid binding protein (H-FABP) is abundant in the cytosol of 
cardiomyocytes and is predominately responsible for intracellular translocation of 
long-chain fatty acids. Its small size (15kDa) and location in the cytoplasm allow for 
quick release into the circulation in response to myocardial injury. H-FABP levels 
are detectable in blood 2-3 hours following initial injury, and they return to normal 
within 12-24 hours. Its kinetics are similar to that of myoglobin; however H-FABP is 
approximately twentyfold more specific than myoglobin for cardiac muscle.(30). 
 H-FABP is a more sensitive marker of cardiac injury than cTn, when 
measured within three hours of symptom onset. Elevated H-FABP levels were 
associated with increased risk of death, MI, or CHF at ten months (Hazard Ratio 2.6; 
95% CI: [1.9, 3.5]), independent of established risk factors, cTnI, BNP, and 
myoglobin. 
In addition to enhancing risk stratification and facilitating very early ACS 
diagnosis in the absence of an elevated cTn, H-FABP also has potential for detection 
of recurrent MI and determining success of reperfusion therapy. 
Inflammatory Markers in Primary Prevention 
 Among the approximately 800,000 people within the United States who suffer 
annually from myocardial infarction or stroke, roughly half have average or even 
low lipid levels and 15 to 20 percent do not exhibit any of the traditional 
Framingham coronary risk factors, such as hypertension, hyperlipidaemia, smoking, 
or diabetes.  
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This suggests that traditional coronary risk factors do not identify a substantive 
portion of apparently healthy men and women who are at a risk for acute coronary 
syndrome (ACS) or acute stroke. 
ADIPONECTIN 
 Adiponectin an adipocytokine family mediator has anti inflammatory,  
pleiotropic and insulin sensitizing properties. Studies by cava sogulu et al [20] 
revealed that elevated adiponectin values are associated with decreased survival rate 
in acute coronary syndromes.  This elevated adiponectin levels are produced by 
high inflammatory milieu which is a feedback physiological response to limit the 
endothelial damage. 
INTERLEUKIN-10 
 Various interleukin family members are associated in cascade event of 
atherosclerotic process .Among this IL-10 was frequently evaluated and has proven 
to be associated with ACS and it is an  independent predictor of adverse outcome in 
acute coronary syndrome-cavasogulu et al[21]. 
ISCHAEMIA MODIFIED ALBUMIN 
IMA is a new biomarker produced in the setting of the reactions between 
reactive oxygen free radicals that are produced due to ischemia of myocardium and 
transition metals (viz. cobalt). The quick rise (few minutes) and fall (2hours) to 
normal levels during symptoms of ACS, make it useful over the other cardiac 
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biomarkers. IMA values seen in the first 24 hours were a strong and absolute marker 
for the cardiovascular consequences at 1 year. 
 
BIOLOGICAL INDICATORS OF PLAQUE DESTABILISATION 
Matrix metalloproteinase and tissue inhibitors of metalloproteinase (23). 
Matrix metalloproteinase are the group of enzymes involved in the disintegration and 
repair of the collagen. MMP-9 is produced before the rupture of plaques and hence 
serves as a vital marker in the identification of ACS and helps to predict its outcome. 
It is useful for identification of early stages and not the late stages of ACS [30].. It 
also serves to predict death in MI patients. Tissue inhibitors of metalloproteinase 
(TIMPs) are found in stable plaques and antagonize MMPs. Levels of TIMP-1 >100 
ng/mL correlates well with poor survival  
MYELOPEROXIDASE (23) 
During the inflammatory responses that occur in ACS, Myeloperoxidase 
(MPO) levels are raised. For the patients with pain in the chest, first time 
determination of MPO values tells the early risk of MI and the risk at 2 years. Levels 
of Plasma MPO correlates with early derangements in plaques in the acute stages 
and are normal in patients with stable CAD. 
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COPEPTIN 
               Copeptin is produced from Vasopressin and is associated with various 
stages of ischemia of myocardium. It helps in the identification of early stages of 
ACS and in ruling out Non ST Elevation MI. (24) 
BIOLOGICAL INDICATORS OF RUPTURE OF THE PLAQUE. 
Soluble CD40 ligand (sCD40L) 
Activation of sCD40 L assembly is found to have importance in the initiation 
of ACS .MI and USA (Unstable angina) patients have high sCD40 levels. They are 
recently found to be associated with worsening during hospitalization [25]. 
PREGNANCY-ASSOCIATED PLASMA PROTEIN A 
 Pregnancy-associated plasma protein A (PAPP-A) is found in fibroblasts of 
humans  and liberated during the rupture of plaques. Even though there were some 
reliable facts during the earlier studies, further studies are needed to evaluate the 
usefulness as an absolute indicator in patients with ACS.  
CHOLINE                                                                                                                                       
Splitting of phospholipids of cell membranes liberates Choline. It is associated with 
unstable plaques in coronaries and platelet rich thrombi and the resultant ischemia. 
An elevated serum choline level tells the probability of MI and differentiates the 
risks of ACS as high and low in a given patient [26].    
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CARDIAC TROPONINS (TROPONIN T AND TROPONIN I) 
Troponins help in the prompt and accurate identification of necrosis of 
myocardium. They start rising within 4-9hr of acute MI, reach highest levels 12-
24hrs and stay in high levels during a maximum of 14 days. Since the troponins have 
more predictive values and advantages over other cardiac biomarkers, Troponins are 
considered as the new gold standard for necrosis of myocytes. They are associated 
with myocardial cell necrosis with high sensitivity and specificity but are not 
specific for ischemia due to CAD.(24) 
 The inclusion of clinical characteristics with troponins helps to differentiate 
ACS and Non ACS patients. High levels of Troponins are linked to higher  
occurrence of short term events and more rates of repeated ischemia that need urgent 
revascularization at  second day  and  at 2 weeks. Thus it helps in prognostication of 
ACS patients. In UA (unstable angina) patients, Troponin I  levels helps in staging of 
early outcome.(27) 
HIGH-SENSITIVITY TROPONIN (HsTnT) 
Highly sensitive assay (high-sensitivity TnT) is a novel method which uses 
the advances in technology of medicine to enable to measure the lower levels in 
plasma than the lower limit of conventional assays. HsTnT values have prognostic 
Values at very low levels in heart failure or stable CAD patients [24]. They have 
higher diagnostic and prognostic importance, when compared to standard TnT levels 
in ACS patients. The superiority of HsTnT estimation helps to avoid other 
biomarkers of necrosis. 
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CREATINE KINASE (CK) AND CK-MB  
             Higher levels of total CK are found not only in cardiac disorders, but also in 
injuries of skeletal muscles and other diseases. Injury of Myocardium shows  
specifically,  higher levels of CK-MB (isoform).It has a fast raise to peak and fall 
during reinfarction  ,proportionately with size of the infarct  and  helps to indicate 
failure of reperfusion. 
MYOGLOBIN                                                                                                                                  
Myoglobin is a protein that binds to oxygen .It is seen in myocardium and skeletal 
muscle in high levels. It is seen in detectable levels within 1 hour of injury and helps 
in its quick identification. It has broad range of normal levels, poor clinical values 
when seen serially and has low specificity and therefore not useful clinically. 
BIOLOGICAL INDICATORS OF STRETCH OR DYSFUNCTION OF 
MYOCARDIUM 
B-TYPE NATRIURETIC PEPTIDE (BNP) AND NT-PROBNP 
Stretching of muscle cells of ventricular myocardium produces BNP .It is 
produced as a prohormone   and split into  N-terminal proBNP (NT-proBNP) and 
then  to BNP. Its role in Heart failure is well documented, but upcoming in Stable 
CAD or ACS. Elevated levels in repeated analysis are linked to 1 year mortality. 
Age and ejection fraction adjusted levels of NT-pro BNP predict mortality 
significantly in patients with ACS and not with clinical heart failure [28]. 
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GROWTH DIFFERENTIATION FACTOR-15 
  It is a member of family of the transforming growth factor-beta cytokine 
response to ischemia and injury after reperfusion .It affects various stages of 
remodelling of heart and is produced during heart failure and in ACS [29].  
MAPPING ATHEROSCLEROSIS 
With the advent of new ant atherosclerotic strategies, it is necessary to 
accurately quantify the response, usually at the target level. For example, lipid-
lowering therapies focus on plasma lipids, and anti-inflammatory drugs focus on 
serum or imaging biomarkers of the inflammatory infiltrate of the plaque .In regard 
to plasma lipids, to monitor the effects of lipid-modulation therapies we are readily 
equipped. Unfortunately, local lipid changes inside the plaque are more difficult to 
monitor. 
Functional PET imaging gained interest to quantity vulnerability of plaque. 
Atherogenesis is a highly active metabolic process and, so is reflected in F-
fluorodeoxyglucose (FDG)   uptake. FDG uptake has been linked with both the 
degree of macrophage infiltration and expression of inflammatory gene, and the 
degree of hypoxia in the atherosclerotic plaque [33]. In view of the fact that the FDG 
uptake in atherosclerosis is a subject of debate, FDG uptake very strongly correlates 
with the risk of recurrent CV events in patients. 
Therefore, new biomarkers, including imaging, are very well suited to 
monitor inflammation and lipoapoptosis in atherosclerosis. Finally, these biomarkers 
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will aid in making important decisions in CV drug development and improving, 
individualizing in the management of patients with high-risk CV disease.  
NOVEL THERAPEUTIC TARGETS IN CV DISEASES (30.31): 
Apart from lipid lowering, the primary focus in CV drug development is to 
inhibit local inflammation. Before looking on novelties, the effect of traditional 
regimens in CV diseases on inflammatory activity needs to be assessed. Statins also 
reduce inflammation independent of their lipid-lowering capacity. Similarly, high-
density lipoproteins have been found to produce potent anti-inflammatory effects. 
Though they are available, high-density lipoprotein cholesterol-increasing therapies 
failed to demonstrate clinical benefit. In addition to modulation of lipid other 
immune-modulating drugs used in chronic inflammatory diseases are used for CV 
patients, like the methotrexate, mycophenolate mofetil and a wide range of other 
biologicals. 
Regarding new anti-inflammatory therapies, it should be kept in mind that 
‘targeting inflammation’ has got three main obstacles: redundancy, compensation 
and inevitability. 
 First, many transducers regulate inflammation and they target one, or even a 
few, may not be sufficient.  
Second, inflammation is slightly regulated, so inhibition of one pathway may 
lead to backfire and produce a proinflammatory response.  
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Third, the inflammatory response is important for our host defence, whereby 
inhibiting inflammation leads to immune suppression. Finally, atherogenic 
nonresolving inflammation has distinct features compared with chronic 
inflammatory diseases, which reflect the heterogeneous nature of both the trigger 
(multifactorial/oxLDL) and the microenvironment (lipid rich).  
So extrapolation of a successful immunosuppressive drug from an immune 
disease to a complex lipid-driven inflammatory process will likely fail. Regarding 
ongoing anti-inflammatory initiatives in CV drug development, there are candidates 
with huge potential, like cytokine targeting, through IL-6 and IL-1 inhibition and 
CCR2 antagonists, though, none of these agents have been able to demonstrate an 
added benefit in atherosclerosis. 
With regards to the three obstacles of inflammation more targeted approaches 
are needed. Till recently interest in nanotechnology was precluded to oncology, but 
it has now also approved attention in CV disease. Nanoparticles can be customized 
to various vehicles, pharmacokinetic qualities and compounds, making it a very 
important novelty for both drug development, and imaging strategies.  
A good example of a potential Nano medical application in atherosclerosis is an anti-
inflammatory PEGylated liposomal nanoparticle containing prednisolone phosphate 
(LN-PLP). LN-PLP has shown improve bioavailability and anti atherogenic effects 
in preclinical models. Notwithstanding demonstrated local delivery of LN-PLP into 
plaque macrophages in vascular patients, the efficacy of liposomal prednisolone to 
decrease arterial wall permeability and inflammation is under investigation. With 
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this successful delivery platform, other compounds can be evaluated as targeted anti 
atherosclerotic strategies.  
Inflammation and inflammatory factors play a substantial role in the 
formation and progression of atherosclerotic plaque, and can lead to determinatively 
acute thrombotic complications of atheroma. Elevated leucocyte count is a marker 
for cardiovascular risk prediction, and the correlation between leucocyte count and 
the risk of cardiovascular disease has been recently demonstrated. However, 
although an increased leucocyte count is related to cardiovascular events and 
mortality in acute coronary syndromes (ACS), recent studies suggest that the 
neutrophil/ lymphocyte ratio (NLR) is a more specific determiner than the neutrophil 
or leucocyte count. Left ventricular systolic dysfunction (LVSD) is an important 
cause both of mortality and morbidity in patients with ACS. In patients with 
ischemic or non-ischemic LVSD, the neutrophil count was demonstrated to be 
related with cardiovascular mortality. Recent studies showed that heart failure (HF) 
develops more frequently in patients with ST elevated ACS who have a high NLR 
on admission to the hospital, and that HF can occur after either a short or long period 
after ACS. Here, we aimed to investigate the predictive value of NLR for LVSD in 
patients with NST-ACS. 
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MATERIALS AND METHODS 
Place of study Thanjavur Medical College, Thanjavur 
Study design Prospective observational study. 
Duration December 2015 to February 2016 
Sample size 55 patients 
 
We enrolled 83 consecutive (collected via simple random sampling method) 
ACS patients admitted in our coronary care unit who had necessary inclusion and 
exclusion criteria and who were subsequently underwent thrombolysis. The patient 
population includes  
 59 STEMI patients. 
 19 NSTEMI patients. 
 5 Un stable angina pectoris (UA) patients. 
 STEMI was if the patient had typical anginal pain persisting more than 20 
minutes, with ECG features of ST elevation for more than 1mm in contiguous frontal 
ECG leads or 2mm or more than 2mm in v1 to v3 or more than 1 mm elevation 
again in other precordial leads. 
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INCLUSION CRITERIA 
 STEMI patients who were thrombolysed  
EXCLUSION CRITERIA are those which affect the NLR ratio like  
 Inflammatory conditions such as collagen-vascular disorders 
 Acute or chronic infectious diseases  
 Auto-immune diseases 
 Neoplastic diseases 
 Chronic hepatic diseases 
 Renal failureThyroid disorders 
 History of cardiac valvular disease.  
 Patients with one or more of these diseases were excluded from the study. 
Totally 3 patients with upper respiratory tract infections and 1 patient with urinary 
tract infection were excluded from the study. On initial admission diagnosis was 
confirmed and Patients were treated as per ACC / AHA protocol. 
In addition the type of chest pain (acute or chronic) and left ventricular 
ejection fraction (LVEF) were documented in the checklist. Those who were active 
smoker at the time of thrombolysis or had quitted smoking in less than one month 
preceding the procedure were considered as smokers. 
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Baseline demographic data were obtained like  
 Age and Gender 
 Cardiovascular diseases risk factors (history of diabetes mellitus, 
hypertension, hyperlipidaemia, cigarette smoking, and alcohol drinking) 
 Laboratory data (triglyceride, fasting blood sugar (FBS), urea, creatinine, 
WBC count, platelet count, MCV (mean corpuscular volume), and NLR were 
entered into a checklist.  
We calculated NLR from the above two parameters. Above values were 
measured with automated cell counter in the department of pathology, Thanjavur 
medical college. All measurements were performed 30 minutes after blood collection 
by an automatic blood counter. 
Echocardiographic examinations were performed according to the guidelines 
of American Society of Echocardiography.  
Definitions 
 Anterior STEMI was defined when a patient had typical chest pain for at least 
30 minutes with >2 mm ST elevation in at least two consecutive anterior 
derivations.  
 Hypertension was considered to be present if the systolic pressure was >140 
mmHg and/or diastolic pressure was >90 mmHg for at least two separate 
measurements, or the previous use of antihypertensive drugs.  
 DM was defined as a fasting blood glucose level >126 mg/dL or current use 
of a diet or medication to lower blood glucose.  
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 Hyperlipidaemia was defined as serum total cholesterol level of 
more than 200 mg/dL, LDL cholesterol level of more than 130 mg/dL, HDL 
cholesterol of less than 40 mg/dL, or triglyceride of higher than 250 mg/dL.   
Statistical analysis 
Pearson Chi-square tests were used to compare the incidence of categorical 
variables among groups. Categorical variables were presented as counts and 
percentages. The two independent sample t tests were used to compare continuous 
variables between the two groups. Continuous variables were presented as mean 
(standard deviation) or as median (ranges). Datas are entered in excel sheat and 
calculations by Chi square tests are done using SSAP software. Calculated p-values 
were considered statistically significant when they were <0.05. 
  
  
52 
 
OBSERVATION AND RESULTS 
 We enrolled 83 consecutive  ( collected via simple random sampling 
method) ACS patient ,among them 59 were STEMI patients (71%),19 were 
NSTEMI patients(18%),5 were USA patients(11%). Totally 3 patients with upper 
respiratory tract infections and 1 patients with urinary tract infection were excluded 
from the study making it a total of 55 STEMI patients for the study pool. Blood 
samples were taken following admission, 24 and 72 hours later. 
Mean age of the patients was 52.08 years. About 41.4% had hypertension, 
18.9% had hyperlipidemia(15 subjects) , 11.4% were smokers, 9% had history of 
alcohol drinking, 13.6% had history of cardiovascular diseases, and 20% had history 
of diabetes mellitus. 
 BASELINE  CHARACTERISTICS OF STUDY SUBJECTS: ( TABLE: 1) 
1. Age 30-40 yrs 4 7% 
2. Age 40-50 yrs 8 14% 
3. Age 50-60 yrs 12 22% 
4.  Age >60 yrs 31 56% 
5. Male  42 76% 
6. Female  13 24% 
7. Smokers 35 64% 
8. Alcoholics  36 67% 
9. Diabetics  35 64% 
11. Hypertensives  39 71% 
10 Dyslipidaemia  15 24% 
11. MI with MACE events 44 79% 
12. MI with arrhythmia 5 10% 
13. MI with hypotension 10 18% 
14. MI with systolic dysfunction 45 82% 
15. Patients with NLR >3 12 22% 
( Table: 1) baseline  characteristics of study parameters 
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MEAN VALUES OF HAEMATOLOGICAL PARAMETERS (TABLE 2): 
 N Range Minimum Maximum Mean SD 
Neutrophil 
admission(%) 55 33 56 89 70.2 8.3 
Neutrophil- 24 hrs 55 44 47 91 69.1 11.8 
Neutrophil-72 hrs 55 24 56 80 66.7 6.8 
Lymphocyte-
admission 55 33 7 40 25.7 8.1 
Lymphocyte-24 hrs 55 41 6 47 27.3 11.6 
Lymphocyte- 72 Hrs 55 23 16 39 28.9 6.3 
Total countAdmission 55 10280 5050 15330 8.7 2601.7 
Total count -24 hrs 55 8250 4950 13200 8.7 2404.7 
Total count – 72 hrs 55 9000 1000 10000 7.11 1855.2 
Ejection fraction 55 35 25 60 43.2 10.4 
NLR  admission 55 9.9 1.6 11.5 3.2 1.8 
NLR – 24 hrs 55 14.1 1.04 15.16 3.6 3.2 
NLR-72 hrs 55 3.5 1.4 5.0 2.4 0.911 
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RELATION BETWEEN NLR AND AGE (TABLE 3): 
Age 
NLR Total Chi - sq P value 
<3 >3  
0.258 0.642 
<40 4 1 5 
>40 39 11 50 
Total 44 11 55 
 
The above table depicts that a total of 39 patients were above 40 yrs and had a 
low NLR ratioo (< cut off of 3). Of the total of 55 patients,11 patients had a above 
cut - off NLR value and were above 40 yrs.There was no significant influence of age 
of the patient on the NLR ratio depicted by a P value of 0.642. 
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RELATION BETWEEN NLR AND SEX OF THE SUBJECT(TABLE 4): 
Sex 
NLR Total Chi - sq P value 
<3 >3  
0.0668 0.796 
Female 2 11 13 
Male 10 32 42 
Total 44 11 55 
 
Among participants in our study there are  42 (76%)  males and  13 ( 24 %)    
females. Female to male ratio is 3:1. 86% among male population develops 
complication .79% among female population develops complication. About 60% 
among male population have raised NLR.90% among female population have raised 
NLR.  There was no significant influence of sex of the patient on the NLR ratio 
depicted by a P value of 0.796.  
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RELATION BETWEEN NLR AND ALCOHOLISM (TABLE 5) 
Alcoholism 
NLR Total Chi - sq P value 
<3 >3  
0.196 0.657 
YES 27(63%) 9(75%) 36 
NO 16(36%) 3(25%) 19 
Total 43(100%) 12(100%) 55 
 
Among alcoholics, 75% have increased NLR value. Among non -alcoholics, 25% 
have increased NLR value. But this is not statistically significant. There was no 
significant influence of alcoholism of the patient on the NLR ratio depicted by a P 
value of 0.657. 
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RELATION BETWEEN NLR AND SMOKING (TABLE 6): 
Smoking 
NLR Total Chi - sq P value 
<3 >3  
0.08 0.92 
YES 27(87.2%) 8(22.8%) 35(100%) 
NO 16(80%) 4(20%) 20(100%) 
Total 44 11 55 
 
Among smokers, 22.8% have increased NLR value. Among non -smokers, 20% have 
increased NLR value. But this is not statistically significant. 
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RELATION BETWEEN NLR AND DIABETES(TABLE 7): 
Diabetes 
NLR Total Chi - sq P value* 
<3 >3  
4.531 
0.033 
Significant 
but inverse 
YES 31(88%) 4(12%) 35(100%) 
NO 12(60%) 8(40%) 20(100%) 
Total 44 11 55 
 
Among diabetics, 12% have increased NLR value. Among non -diabetics, 40% have 
increased NLR value. But this is statistically significant and inversely significant. 
There was a significant negative influence of diabetic status of the patient on the 
NLR ratio depicted by a P value of 0.033. 
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RELATION BETWEEN NLR AND HYPERTENSION (TABLE 8): 
Hypertension 
NLR Total Chi – sq P value 
<3 >3  
0.5074 0.476 
YES 29(74%) 10(26%) 39(100%) 
NO 14(87%) 2(13%) 16(100%) 
Total 43 12 55 
 
Among hypertensives, 26% have increased NLR value. Among non-hypertensives 
,20% have increased NLR value. There was no significant influence of hypertensive 
status  of the patient on the NLR ratio depicted by a P value of 0.476. 
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RELATION BETWEEN NLR AND DYSLIPIDEMIA (TABLE 9): 
Lipid profile 
TGL 
NLR Total Chi – sq P value 
<3 >3  
0.4571 0.24 
<  250 
>250 
32 8 40 
11 4 15 
Total 43 12  
 
Among those with dyslipidaemia,  27%   have increased NLR value. Among those 
with normal triglyceride,  20 % have increased NLR value. But this is not   
statistically significant. 
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ANALYSIS FOR POST-STEMI COMPLICATIONS IN RELATION TO  
NEUTROPHIL-TO-LYMPHOCYTE RATIO: 
POST MI COMPLICATION : 
     In the total of 55 patients, post MI complication was observed in 44 subjects 
(80%) and 11 subjects (20%) were discharged without complication .Minimum NLR 
value observed was 1.35 and maximum value observed was 5.90. Hypotension found 
in18 % of total population and forms 23%age of total patients with infarction .High 
NLR seen in 10% of people with complications.We divided patients into two groups 
one with high NLR > 3.0 and other group with low NLR <3.0. 12 patients (22%) had 
NLR value above 3.0 and remaining 43(78%) patients had NLR value below 3.0 
before analysing for the relation of NLR to different complications. NLR value in 
our study population has mean value of 3.367 (SD+/- 0.9778) minimum. 
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RELATION BETWEEN POST MI COMPLICATION AND ALCOHOLISM 
(TABLE 10) 
 
 
Among alcoholics, 78% had increased post MI complications. Among non-
alcoholics, 84% had increased post MI complications. But this is not statistically 
significant which was indicated by the P value of 0.831. 
  
 
Alcoholism 
Complication post MI Total Chi - sq P value 
YES NO  
0.045 0.831 
YES 28(78%) 8(22%) 36(100%) 
NO 16(84%) 3(16%) 19(100%) 
Total 44 11 55 
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RELATION BETWEEN POST MI COMPLICATION AND SMOKING 
(TABLE 11) 
Smoking     Complication post MI Total Chi - sq P value 
YES NO  1.104 0.629 
YES 30(86%) 5(14%) 35(100%) 
NO 14(70%) 6(30%) 20(100%) 
Total 44 11 55 
 
Among smokers, 86% had increased post MI complications. Among non -smokers, 
14% had increased post MI complications. There was no significant influence of 
smoking status of the patient on the NLR ratio depicted by a P value of 0.629. 
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RELATION BETWEEN POST MI COMPLICATION AND DIABETES 
(TABLE 12) 
diabetes 
Complication post MI Total Chi - sq P value 
YES NO  
0.122 0.726 
YES 29(83%) 6(17%) 35(100%) 
NO 15(75%) 5(25%) 20(100%) 
Total 44 11 55 
 
Among diabetics, 83% had increased post MI complications. Among non -diabetics, 
75% had increased post MI complications. There was no significant influence of 
diabetic status  of the patient on the NLR ratio depicted by a P value of 0.726. 
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RELATION BETWEEN POST MI COMPLICATION AND 
HYPERTENSION( TABLE 13) 
Hypertension 
Complication post MI Total Chi – sq P value 
YES NO  
0.0496 0.823 
YES 31(79%) 8(21%) 39(100%) 
NO 13(81%) 3(19%) 16(100%) 
Total 44 11 55 
 
Among hypertensives, 79% had increased post MI complications. Among non - 
smokers, 81% had increased post MI complications. There was no significant 
influence of hypertensive status of the patient on the NLR ratio depicted by a P value 
of 0.823. 
  
  
75 
 
 
 
 
RELATION OF NLR RATIO AND ELECTROCONDUCTIVE 
DISTURBANCE (TABLE 14) 
 
The above table depicts that a total of 5 patients had arrhythmogenic complication. 
Of the total of 5 patients with electroconductive complications, 2 patients had a NLR 
value above the cut - off value of 3 and 3 patients had a NLR value below the cut - 
off value of 3.There was a significant influence of NLR  of the patient on the 
incidence  depicted by a P value of 0.642. 
 
 
 
 
Arrhythmias 
NLR Total Chi - sq P value 
<3 >3  
0.2158 0.643 
YES 3 2 5 
NO 40 10 50 
Total 43 12 55 
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RELATION OF  NLR AND LVEF(TABLE 15) 
LVEF 
NLR Total Chi - sq P value 
<3 >3  
0.0137 0.906 
Normal 9 2 11 
Decreased 34 10 44 
Total 43 12 55 
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RELATION OF NLR AND HYPOTENSION(TABLE 16) 
Hypotension 
NLR Total Chi - sq P value 
<3 >3  
2.026 0.154 
YES 10 0 35(100%) 
NO 33 12 20(100%) 
Total 43 12 55 
 
Arrhythmia seen 10% of people with infarction .among them 17% found to have 
high NLR.LV dysfunction is seen in 82% of people with infarction. Among them 
22% found to have raised NLR. 
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DISCUSSION 
 
 Acute myocardial infarction is associated with leukocytosis which was a well 
known fact. The differential analysis of white blood cells like the newer parameter 
Neutrophil lymphocyte ratio( NLR ) gives additional benefit of assessing ACS 
severity by clinical outcomes and gives complexity and severity of plaque burden on 
admission by a simple and easily available blood test. This elevated NLR was a 
quantum of neutrophils to lymphocytes irrespective of total count. 
 
  In our study group, we have compared influence of co-factors like age, sex, 
elevated triglyceride level, hypertension, alcohol, smoking and diabetes with the 
incidence of MACE events and their association with NLR level . Majority of the 
selected cases are above 60 yrs of age. On analysis, it was found that there is no role 
of age in influencing NLR level. Smoking have a positive correlation with 
complications and diabetes have negative correlation with NLR. No other co –
factors was found to be significantly associated with complication or NLR. We 
found that high NLR is associated with the post infarction complications but it is not 
statistically significant.  
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We demonstrated that following STEMI the numbers of white blood cells, 
mostly in the form of neutrophils, were higher . Increased neutrophil count was 
associated with higher in-hospital morbidity, post-infarction pump failure and 
occurrence of serious ventricular arrhythmias. Similar reports by Menonet al., 
suggested that patients with higher leukocyte count were at high risk of heart failure 
and cardiogenic shock.(34) Barron et al. demonstrated that there was an association 
between high leukocyte count and incidence of cardiogenic shock or congestive 
heart failure.(35) They reported a higher mortality in patients with more intense 
increase in WBC count. A similar linear correlation was observed between in-
hospital mortality and increasing white blood cells count in the blood (36). However, 
they found that the NLR was inferior to the absolute number of the neutrophils in 
predicting in-hospital mortality.  
 
 
          Association between higher neutrophil count and heart failure has been 
stressed in several studies.(38,39) Chia et al. showed that elevated leukocyte and 
neutrophil counts after primary PCI in patients with STEMI were associated with 
larger myocardial infarct size and lower LVEF and were independent predictors of 
cardiovascular outcome.(40) Similarly, our study patients with evidence of heart 
failure as low EF had higher neutrophil count  and NLR ratio.  
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The association between inflammation and atrial fibrillation is well 
studied.(41).  We did not use routine holter monitoring in our patients and detailed 
arrhythmia evaluation was not possible after second or third day when patients were 
transferred from CCU and this may be a confounding factor for this analysis. Data 
regarding association of ventricular arrhythmias with CBC results are 
conflicting.(43) Chatterjee et al. reported that pre-procedural elevated WBC count, 
neutrophilia and elevated NLR in patients undergoing PCI were significant 
predictors of ventricular arrhythmias.(44) In our study, higher WBC, neutrophil 
count and NLR were found to be associated in patients who developed  arrhythmias  
though statistically not significant.  
 
In summary, our study showed that neutrophil lymphocyte ratio is a simple 
and widely available test which may be helpful to identify STEMI patients who have 
a high incidence of heart failure and arrhythmias there by helping  in risk 
stratification of these cases.  
 
The other blood cell parameters easily available on bedside like Mean platelet 
volume, Platelet and lymphocyte ratio and red cell distribution width were also 
analyzed in other studies to evaluate the inflammatory and thrombogenic potential 
associated with ACS. In the current study, we evaluated the leukocytic response to 
STEMI and examined its possible association with post-infarction complication . 
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We performed a average CBC analysis taken at the time of 
admission,24hrs,72hrs to show the value of this inexpensive and widely available 
test in risk stratification post-STEMI complications. This was based on the findings 
of Nunez et al. that showed highest neutrophil and lowest lymphocyte counts and 
maximum NLR in 12-24 h,  associated with more morbidity and mortality. 
 
This study has a number of limitations. First, this was a single center and 
cross-sectional study in which only in hospital  NLR values were calculated. Follow- 
up values of these parameters and their relation to clinical prognosis were not 
evaluated. Second, other parameters (C-reactive protein, interleukin 6, serum soluble 
adhesion molecule levels, etc.) as markers for inflammatory status and their 
association with PLR, NLR values and TFC values were not investigated. Lastly, 
low patient number was another limitation of our study, which could have an effect 
on the broader applicability of our conclusions. 
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CONCLUSION 
This study which was intended to find out the role of NLR in assessing risk 
stratification of STEMI, showed positive correlation . Though stastically not 
significant, our findings support  the role of inflammation in the pathogenesis of post 
MI complications. Thus, NLR assessments which are routinely performed upon 
admission and universally available, may be considered in future  practice for 
prediction of post MI complications. But we are in need to extent this study, by 
conducting it in multiple centers and involving larger population, for better risk 
stratification.  
 
 
  
 
 
. 
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CONSENT FORM 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR .ANUREKHA G, Post graduate in the 
Department of  General Medicine ,Thanjavur Medical College & Hospital, 
Thanjavur – 613004 and to use my personal clinical data and result of investigation 
for the purpose of analysis and to study the nature of disease. I also give consent for 
further investigations 
 
 
Place : 
Date :       Signature of participant 
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INFORMATION SHEET 
 
We are conducting a prospective study on A study on prognostic significance of 
neutrophil lymphocyte ratio  in  patients  with STEMI in the Department of 
General Medicine , Thanjavur Medical College & Hospital, Thanjavur – 613004. 
• At the time of announcing the results and suggestions, name and identity of 
the patients will be confidential. 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment.  
 
 
Signature of investigator  Signature of participant 
 
Date: 
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PROFORMA: 
 
TITLE: A study on prognostic significance of neutrophil lymphocyte ratio  in  
STEMI patients  . 
INVESTIGATOR :R.ANUREKHA G       MD (GENERAL MEDICINE)  P.G 
GUIDE:   DR.C.GANESAN M.D. , 
CHIEF CO-ORDINATOR : Prof.  Dr.C.GANESAN  M.D. , 
Window period 
 
                                Hrs 
H/O MI  
HABIT Smoking                                      Alcoholic 
TIMI score  
KILLIP stage  
Blood pressure 
assessment 
 
                               MmHg 
Fasting triglyceride level 
 
                                mg/dl          
FBS  /Random 
 
                               mg/dl 
CBC at  
Admission 
 
24 hrs 
 
72 hrs  
 
At discharge 
 
TC Neutro Lympho Miscell 
    
    
    
    
 
  
94 
 
Renal function test 
 
Urea               
mg/dl 
Cr               mg/dl 
 
ESR 
 
                                   mm/hr 
C-reactive protein 
 
                                    
Electrocardiography 
 
Rhythm:                          Rate: 
 
ST elevation:     YES/NO 
 
If yes, leads involved:                   Amplitude:   
 
T-wave inversion:  
 
Other changes: 
Reciprocal changes       :  YES/NO 
 
LVH                                : YES/NO 
 
QRS morphology -  Normal: YES/NO 
 
 
Arrhythmias                   :YES/NO 
 
Type: 
 ECHO 
CARDIOGRAPHY  
Hypotension YES/NO 
Requirement of 
defibrillation: YES/NO 
Period in hospital :  
MACE events:  
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Patient phone no:                                                       
 
 
 Patient name:                      Age: 
Patient IP no:                                                              Unit: 
 
 Killip classification: 
Class I: No evidence of heart failure (mortality 6%) 
Class II: Findings of mild to moderate heart failure (S3 gallop, 
rales < half-way up lung fields or elevated jugular venous 
pressure (mortality 17%) 
Class III: Pulmonary edema (mortality 38%) 
Class IV: Cardiogenic shock defined as systolic blood pressure < 
90 and signs of hypoperfusion such as oliguria, cyanosis, and 
sweating. (mortality 67%) 
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2 F 60 44645 n no no YES 294 81 56 66 7 44 31 7200 8500 4450 Y NO 38 NO
3 M 35 46293 yes no yes YES 98 73 51 56 16 45 39 7800 5950 6000 Y no 30 no
4 M 30 44577 yes no yes NO 150 62 85 72 26 14 25 6800 12150 10500 N no 50 no
5 M 30 44839 yes yes yes YES 320 66 62 57 21 36 39 10900 5850 8000 Y no 38 NO
6 F 65 44902 no no yes NO 190 61 57 61 26 40 34 9500 4950 9200 Y NO 45 YES
7 M 74 45592 yes no no YES 56 61 72 58 26 27 37 6100 8450 8000 Y NO 45 NO
8 M 48 45645 no yes no YES 140 61 83 72 26 16 25 11700 10550 6590 Y NO 40 NO
9 M 51 45700 yes no no NO 70 73 67 67 12 22 30 12300 7200 Y YES 60 NO
10 F 75 47050 no no no YES 96 73 73 57 16 20 39 11600 10950 9650 N NO 60 NO
11 F 50 47087 no no yes NO 103 60 64 64 28 31 32 5200 6750 1000 Y NO 45 NO
12 M 40 46658 yes yes no NO 290 56 62 61 32 34 34 7200 10350 7000 Y NO 25 YES
13 M 55 44966 yes yes no YES 294 81 52 66 11 44 31 7100 9050 4000 Y NO 38 NO
14 M 66 40421 no no yes YES 98 73 47 56 16 45 39 7850 6050 8690 Y no 30 no
15 M 75 40370 yes no yes YES 150 62 84 72 26 16 25 6850 12350 6900 N no 50 no
16 F 73 40694 no no no YES 320 66 58 57 21 40 39 10950 5950 7800 Y no 38 NO
17 M 42 40641 yes yes yes NO 190 61 53 61 26 47 34 9550 5100 9000 Y NO 45 YES
18 M 47 41376 yes no yes YES 56 61 68 58 26 29 37 6150 8540 7900 Y NO 45 NO
19 F 55 41096 no no no YES 140 61 83 72 26 15 25 11750 10550 6300 Y NO 40 NO
20 M 74 41496 yes yes yes NO 70 73 67 67 12 30 30 12350 4950 Y YES 60 NO
S. 
NO. S
E
X
A
G
E
I
P
 
N
O
s
m
o
k
e
r
a
l
c
o
h
o
l
i
c
d
m
H
T
F
A
S
T
I
N
G
 
T
G
L
N
 
-
A
N
-
2
4
N
-
7
2
L
-
 
A
L
-
2
4
L
-
7
2
T
C
 
A
 
T
C
 
2
4
T
C
 
7
2
C
O
M
P
 
Y
/
N
A
r
r
h
y
t
h
m
i
a
s
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
H
y
p
o
t
e
n
s
i
o
n
21 M 41 41035 yes yes no NO 96 72 73 57 16 24 39 11650 11150 8050 N NO 60 NO
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25 M 44 42434 no yes yes YES 98 73 47 56 16 43 39 7850 6000 7800 Y no 30 no
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27 F 65 42629 no no no NO 320 74 66 57 21 31 31 10900 5800 7800 Y no 38 NO
28 M 48 42935 yes no no NO 190 69 61 69 34 40 26 9500 4950 5650 Y NO 45 YES
29 M 40 36307 yes yes yes YES 56 69 76 66 34 23 29 5900 8000 7550 Y NO 45 NO
30 F 60 36333 no no yes YES 140 69 91 80 34 6 17 11400 10300 9050 Y NO 40 NO
31 M 75 36561 yes no no NO 70 81 75 75 20 21 22 12300 7500 Y YES 60 NO
32 M 45 37305 no yes yes YES 96 81 81 65 24 13 31 11400 11000 9500 N NO 60 NO
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36 M 65 37995 no yes no YES 98 81 55 64 24 37 31 6600 10150 6300 Y no 30 no
37 M 71 38583 no no yes YES 150 70 89 80 34 8 17 6500 12100 5300 N no 50 no
38 M 60 38798 yes no yes YES 320 74 66 65 29 31 31 10750 5800 4800 Y no 38 NO
39 M 65 39472 yes yes no YES 190 69 61 69 34 39 26 9250 5200 9150 Y NO 45 YES
40 M 65 39806 yes no yes NO 56 69 76 66 34 20 29 6150 8300 8100 Y NO 45 NO
S. 
NO. S
E
X
A
G
E
I
P
 
N
O
s
m
o
k
e
r
a
l
c
o
h
o
l
i
c
d
m
H
T
F
A
S
T
I
N
G
 
T
G
L
N
 
-
A
N
-
2
4
N
-
7
2
L
-
 
A
L
-
2
4
L
-
7
2
T
C
 
A
 
T
C
 
2
4
T
C
 
7
2
C
O
M
P
 
Y
/
N
A
r
r
h
y
t
h
m
i
a
s
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
H
y
p
o
t
e
n
s
i
o
n
41 M 60 40044 no yes yes YES 140 69 91 80 34 7 17 11550 11600 7150 Y NO 40 NO
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43 F 53 39663 no no yes YES 96 81 81 65 24 13 31 12250 10500 10000 N NO 60 NO
44 M 65 39794 yes yes yes NO 103 68 72 72 36 23 24 6150 7800 7700 Y NO 45 NO
45 M 71 44839 yes no no YES 290 64 70 69 40 26 26 7400 11300 8100 Y NO 25 YES
46 M 65 44966 yes no yes YES 298 89 60 74 17 36 23 7200 9300 5300 Y NO 38 NO
47 M 35 44577 yes yes yes YES 96 81 55 64 24 37 31 7800 6200 Y no 30 no
48 F 60 44645 no no no YES 160 70 89 80 34 8 17 7000 13200 N no 50 no
49 F 65 44902 no no yes YES 304 74 66 65 29 31 31 11350 6000 Y no 38 NO
50 F 53 45336 no no no YES 194 69 61 69 34 39 26 10000 5700 9300 Y NO 45 YES
51 M 48 45645 yes yes yes YES 59 69 76 66 34 20 29 6400 8900 7950 Y NO 45 NO
52 M 35 46293 no yes yes YES 147 69 91 80 34 7 16 11800 10800 7700 Y NO 40 NO
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